NCT06206174View on ClinicalTrials.gov

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2029

Conditions
Hematologic MalignancyNon Hodgkin LymphomaAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia, AdultMyelodysplastic Syndromes
Interventions
DRUG

TGRX-814

Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY